title: Does patient education work in breast cancer? Final results from the global CARIATIDE study.
abstract: OBJECTIVE
  To determine the impact of educational materials (EMs) on the treatment compliance of postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer.
  
  
  METHODS
  Patients (n = 2757) were randomized to standard aromatase inhibitors (AI) alone (group A) or with EMs (group B) in a global, real-world setting.
  
  
  RESULTS
  The 2-year results (n = 2242) showed EMs had no impact on compliance (82 vs. 82%, group A vs. B), compliance with initial AI (82 vs. 81%) or persistence (90 vs. 88%), confirming the 1-year interim analysis (n = 2567). Of the 2082 patients considered compliant at 1 year, 77% remained compliant at 2 years. Discontinuations (9%) were mainly attributed to AI-related side effects (68% of discontinuations). Exploratory analyses suggest a relationship between patient characteristics and compliance behaviors.
  
  
  CONCLUSIONS
  EMs do not improve compliance in this patient population. Compliance and persistence are complex end points influenced by multiple variables. Side effects were the main reasons for discontinuations.
authors.affiliation: Breast Unit, Athens University Medical School, Athens, Greece.
authors.forename: Christos
authors.initials: C
authors.lastname: Markopoulos
authors.forename: Patrick
authors.initials: P
authors.lastname: Neven
authors.forename: Minna
authors.initials: M
authors.lastname: Tanner
authors.forename: Michael
authors.initials: M
authors.lastname: Marty
authors.forename: Rolf
authors.initials: R
authors.lastname: Kreienberg
authors.forename: Louise
authors.initials: L
authors.lastname: Atkins
authors.forename: Ann
authors.initials: A
authors.lastname: Franquet
authors.forename: Michael
authors.initials: M
authors.lastname: Gnant
authors.forename: Silvia
authors.initials: S
authors.lastname: Neciosup
authors.forename: Petra
authors.initials: P
authors.lastname: Tesarova
authors.forename: Sandro
authors.initials: S
authors.lastname: Barni
authors.forename: Veronique
authors.initials: V
authors.lastname: Deschamp
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D008875:Middle Aged; D000077384:Anastrozole; D000730:Androstadienes / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D000077289:Letrozole; D009570:Nitriles / Q000008:administration & dosage; D010349:Patient Compliance; D010353:Patient Education as Topic; D013629:Tamoxifen / Q000008:administration & dosage; D014230:Triazoles / Q000008:administration & dosage
chemical_list: D000077384:Anastrozole; D000730:Androstadienes; D047072:Aromatase Inhibitors; C056516:exemestane; D000077289:Letrozole; D009570:Nitriles; D013629:Tamoxifen; D014230:Triazoles
keywords: adherence; anastrozole; aromatase inhibitor; breast cancer; compliance; letrozole; persistence